Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Amyris Jumped as Much as 28.9% Today

By Maxx Chatsko - Updated Apr 15, 2019 at 3:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The business received a small lifeline from one of its largest shareholders.

What happened

Shares of Amyris (AMRS -14.02%) jumped nearly 29% today, after the company announced progress in its efforts to repay convertible debt notes bearing an interest rate of 9.5% that were due today. The pioneer in synthetic biology told investors it expects to repay the notes with "cash from a business transaction" and a planned equity investment from Foris Ventures, a fund affiliated with Amyris director John Doerr.

Repaying and retiring the notes in full will avoid significant stock dilution from the $57.6 million of original debt, which was scheduled to be payable in over 3.3 million shares of common stock. That's not much, relatively speaking, but considering Amyris has seen its share count explode from 25 million in mid-2017 -- following a 1-for-15 stock split -- to over 73 million today, investors are rewarding management for trying.

As of 2:30 p.m. EDT, the stock had settled to a 12.2% gain.

A businessman drawing a yellow step chart rising higher

Image source: Getty Images.

So what

The full details of the transactions and equity investments weren't disclosed, but a separate filing with the Securities and Exchange Commission shows that Foris Ventures is extending an $8 million credit facility in the form of a promissory note to Amyris. The note is due in six months and was accompanied by a fee of $1 million, equivalent to a 12.5% interest rate.

That still leaves Amyris in need of an additional $50 million to retire the 9.5% notes in full. It doesn't exactly have a lot of bargaining power. After all, it recently disclosed that it overstated full-year 2018 revenue by at least $12 million -- or at least 15% of the total -- due to miscalculated royalty payments. Investors who read SEC filings could have seen that coming.

Now what

Missing guidance by 58%, overstating revenue, taking out new debt to repay old debt: Amyris stock is surrounded by flashing red lights warning individual investors to stay away. While the company continues to walk the tightrope of debt financing, exchanging one form of debt for another, its future is completely dependent on its ability to commercialize products from its research and development projects. Its failure to do so to date shouldn't be taken lightly by investors. Expect the stock to remain volatile.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amyris, Inc. Stock Quote
Amyris, Inc.
$2.27 (-14.02%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.